Results 161 to 170 of about 326,761 (272)

An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon‐like peptide‐1 and glucagon receptor in healthy subjects

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Glucagon‐like peptide‐1 (GLP‐1) and glucagon dual receptor agonists are in clinical development for a range of metabolic conditions, including type 2 diabetes and obesity. The cardiovascular actions at these receptors are well studied, but less is known about their combination.
James Goodman   +13 more
wiley   +1 more source

Absolute bioavailability and intravenous pharmacokinetics of N‐acetyl‐D‐mannosamine in humans

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims N‐acetyl‐D‐mannosamine monohydrate (ManNAc) is a naturally occurring monosaccharide that has attracted considerable attention for its potential in treating GNE myopathy, a rare autosomal recessive muscle disorder. Despite its promise as an oral treatment, the absolute bioavailability of oral ManNAc has not been determined and there has been no ...
Tahlia R. Meola   +6 more
wiley   +1 more source

Common on “craniorachischisis in a stillbirth associated with maternal smoking”

open access: yesTaiwanese Journal of Obstetrics & Gynecology
Fenglin Jiang
doaj   +1 more source

Quiz (Electrocardiogram)

open access: yesJournal of the Practice of Cardiovascular Sciences, 2016
Neeraj Parakh, Sandeep Singh
doaj   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Crisugabalin is a novel calcium channel α2δ subunit ligand and a highly selective oral gamma‐aminobutyric acid (GABA) analogue developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN). This study investigated pharmacokinetic properties and safety of crisugabalin in subjects with renal impairment ...
Shibeilei Lin   +6 more
wiley   +1 more source

Electrocardiogram quiz

open access: yesJournal of the Practice of Cardiovascular Sciences, 2015
Praloy Chakraborty
doaj   +1 more source

Home - About - Disclaimer - Privacy